Outpatient Management of COVID-19 With Monoclonal Antibody Therapy in a Young Renal Transplant Patient

Malik, Bilal Haider; Kalantary, Atefeh; Rikabi, Kamal; Abdelazeem, Basel; Kunadi, Arvind

doi:10.7759/cureus.17672

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, systematic reviews and meta-analyses are at the top of the clinical evidence hierarchy and can decide whether nutraceutical agents should be used in the clinical setting. Fortunately, there were recent advances in the management of COVID-19, including antiviral agents, monoclonal antibodies along with supportive care measures, oxygen therapy, and usage of corticosteroids (28)(29)(30). The purpose of this systematic review is to highlight the multi-therapeutic effects of curcumin as a dietary supplement in reducing inflammation, relieving the symptoms of COVID-19, and accelerating the recovery process.…”

Section: Discussionmentioning

confidence: 99%

The effects of curcumin as dietary supplement for patients with COVID-19: A systematic review of randomized clinical trials

Abdelazeem

Awad

Elbadawy

et al. 2022

DD&T

Self Cite

View full text Add to dashboard Cite

Accumulating evidence has been reported regarding the effect of curcumin as a dietary antiviral on patients with COVID-19; however, findings are controversial. Our systematic review aimed to evaluate the effects of curcumin in patients with COVID-19. Electronic databases (PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar) were systematically searched to identify only randomized clinical trials (RCTs) that assessed curcumin in patients with COVID-19 from inception to September 23, 2021 relevant keywords. The Cochrane risk-of-bias tool for randomized trials was used to evaluate the risk of bias. After a critical review of 1,098 search hits, only six RCTs were selected for discussion. A total of 480 patients were included, with 240 amongst the curcumin groups and 240 in the control group. The lymphocyte count was significantly higher in the curcumin group compared to the placebo group. Curcumin was found to decrease the number of T-helper 17 cells, downregulate T-helper-17 cell-related factors, reduce levels of T-helper-17 cell-related cytokines, yet increase the gene expression of Treg transcription factor forkhead box P3 (FOXP3), and decrease T-Box transcription factor 21 (TBX21). Our review revealed that curcumin might have a positive effect on relieving COVID-19 related inflammatory response due to its powerful immune-modulatory effects on cytokines production, T-cell responses, and gene expression. These findings suggest that curcumin confers clinical benefits in patients with COVID-19. However, due to the limited number of the included studies, further high-quality studies are needed to establish the clinical efficacy of the curcumin.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of curcumin as dietary supplement for patients with COVID-19: A systematic review of randomized clinical trials

Abdelazeem

Awad

Elbadawy

et al. 2022

DD&T

Self Cite

View full text Add to dashboard Cite

show abstract

“…Virus-neutralizing monoclonal antibodies (mAbs) are safe and efficient in reducing SARS-CoV-2 viral load in both immunocompetent and immunocompromised outpatients, including solid organ transplant recipients [4][5][6]. Combined with immunosuppression reduction [7,8], mAbs are recommended for solid organ or hematopoietic stem cell transplant recipients with mild to moderate COVID-19 who are at an increased risk of progressing to severe disease [9]. The US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple mAbs therapies for the treatment or postexposure prophylaxis of COVID-19 in patients with certain high-risk conditions [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

Background: The use of virus-neutralizing monoclonal antibodies has been approved in fragile populations, including kidney transplant recipients, who are at risk of developing severe COVID-19. Sotrovimab is the only currently available anti-SARS-CoV-2 neutralizing monoclonal antibody with activity against the new Omicron variant of concern. While sotrovimab has been approved in adolescents and adults, studies regarding its efficacy and safety in children aged less than 12 years old and weighing less than 40 kg are still lacking. Here, we report a first case of a child, who was treated early with sotrovimab after a kidney transplant. Case Report: At the end of January 2022, a 11-year-old male child underwent a deceased-donor kidney transplant and became infected with SARS-CoV-2 during the first day after surgery. Due to the increased risk of developing severe COVID-19, based on the predominance of Omicron and the patient’s renal function, the child was treated with sotrovimab. The clinical course was successful and no adverse reactions were reported. Conclusions: For the first time, we report the well-tolerated use of sotrovimab in children under 12 years old. As the pandemic affects children across the globe, urgent data on sotrovimab dosing in children with a higher risk of developing severe COVID-19 are needed.

show abstract

Outpatient Management of COVID-19 With Monoclonal Antibody Therapy in a Young Renal Transplant Patient

Abstract: Malik et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Cited by 2 publications

References 14 publications

The effects of curcumin as dietary supplement for patients with COVID-19: A systematic review of randomized clinical trials

The effects of curcumin as dietary supplement for patients with COVID-19: A systematic review of randomized clinical trials

Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2

Contact Info

Product

Resources

About